Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q5530845> ?p ?o }
Showing triples 1 to 70 of
70
with 100 triples per page.
- Q5530845 subject Q6620534.
- Q5530845 subject Q8301163.
- Q5530845 subject Q8401077.
- Q5530845 abstract "GenSpera, Inc. (OTC:QB GNSZ) is a development-stage pharmaceutical company based in San Antonio, Texas. The company is focused on therapeutics that deliver a cancer-destroying drug directly to the tumor or its supporting environment, the tumor vasculature.The company's prodrug technology renders the drug inactive until it encounters the programmed target, thereby delivering the cytotoxin directly to the cancer or the vessels that support it, while potentially avoiding the side effects associated with current chemotherapies. A prodrug is an inactive precursor of a drug that is converted into its active form at a targeted site.GenSpera's lead drug candidate, G-202, is currently in a Phase II clinical trial for patients with hepatocellular carcinoma (HCC) whose disease has failed to improve on standard therapy for this indication. G-202 is also being evaluated in a Phase II clinical trial in glioblastoma patients with recurrent disease after surgery and/or radiation treatment of the primary tumor. G-202 targets the enzyme PSMA, found on the walls of blood vessels that feed most cancerous tumors, destroying the tumor blood supply. In contrast with anti-angiogenic agents, G-202 destroys existing as well as new cancer blood vessels. G-202 received Orphan Drug Designation from U.S. Food and Drug Administration for the treatment of HCC, the most common form of primary liver cancer.The company also holds patents on prodrug candidates that target the prostate-specific enzymes Prostate Specific Antigen (PSA) and Human Glandular Kallikrein (hK2). These candidates are expected to be useful in the treatment of prostate cancer.The active ingredient in G-202 is a chemotherapeutic agent derived from thapsigargin, a plant-based cytotoxin that kills by disrupting the calcium balance in cancer cells. GenSpera's prodrug delivery system keeps the thapsigargin inactive in the body until it finds cells that it has been programmed to seek. Once those cells in the body are found, the prodrug releases its active ingredient and destroys all of the targeted cells.The National Cancer Institute had previously demonstrated that thaspigargin was ten-to-a-hundredfold more potent than traditional chemotherapeutic agents in killing all types of cells. Thapsigargin kills cells irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers as well as cancer stem cells.".
- Q5530845 foundingYear "2003".
- Q5530845 industry Q507443.
- Q5530845 keyPerson Q1255921.
- Q5530845 keyPerson Q140686.
- Q5530845 keyPerson Q484876.
- Q5530845 keyPerson Q623268.
- Q5530845 keyPerson Q623279.
- Q5530845 locationCity Q1439.
- Q5530845 locationCity Q975.
- Q5530845 numberOfEmployees "2".
- Q5530845 type Q891723.
- Q5530845 wikiPageExternalLink genspera.com.
- Q5530845 wikiPageExternalLink www.genspera.com.
- Q5530845 wikiPageWikiLink Q1255921.
- Q5530845 wikiPageWikiLink Q1367466.
- Q5530845 wikiPageWikiLink Q140686.
- Q5530845 wikiPageWikiLink Q1439.
- Q5530845 wikiPageWikiLink Q1466447.
- Q5530845 wikiPageWikiLink Q14859580.
- Q5530845 wikiPageWikiLink Q14912954.
- Q5530845 wikiPageWikiLink Q15427523.
- Q5530845 wikiPageWikiLink Q172847.
- Q5530845 wikiPageWikiLink Q1808012.
- Q5530845 wikiPageWikiLink Q186285.
- Q5530845 wikiPageWikiLink Q1930860.
- Q5530845 wikiPageWikiLink Q207011.
- Q5530845 wikiPageWikiLink Q246181.
- Q5530845 wikiPageWikiLink Q3824358.
- Q5530845 wikiPageWikiLink Q3981006.
- Q5530845 wikiPageWikiLink Q423285.
- Q5530845 wikiPageWikiLink Q484876.
- Q5530845 wikiPageWikiLink Q507443.
- Q5530845 wikiPageWikiLink Q539568.
- Q5530845 wikiPageWikiLink Q603741.
- Q5530845 wikiPageWikiLink Q623268.
- Q5530845 wikiPageWikiLink Q623279.
- Q5530845 wikiPageWikiLink Q6620534.
- Q5530845 wikiPageWikiLink Q664846.
- Q5530845 wikiPageWikiLink Q72499.
- Q5530845 wikiPageWikiLink Q8301163.
- Q5530845 wikiPageWikiLink Q8401077.
- Q5530845 wikiPageWikiLink Q858729.
- Q5530845 wikiPageWikiLink Q891723.
- Q5530845 wikiPageWikiLink Q901227.
- Q5530845 wikiPageWikiLink Q975.
- Q5530845 foundation "2003".
- Q5530845 industry Q507443.
- Q5530845 keyPeople "*Craig Dionne, PhD *Russell Richerson, PhD".
- Q5530845 locationCity Q1439.
- Q5530845 locationCity Q975.
- Q5530845 name "GenSpera, Inc.".
- Q5530845 numEmployees "2".
- Q5530845 type Q891723.
- Q5530845 type Organization.
- Q5530845 type Agent.
- Q5530845 type Company.
- Q5530845 type Organisation.
- Q5530845 type Agent.
- Q5530845 type SocialPerson.
- Q5530845 type Thing.
- Q5530845 type Q43229.
- Q5530845 comment "GenSpera, Inc. (OTC:QB GNSZ) is a development-stage pharmaceutical company based in San Antonio, Texas.".
- Q5530845 label "GenSpera".
- Q5530845 homepage genspera.com.
- Q5530845 homepage www.genspera.com.
- Q5530845 name "GenSpera, Inc.".